AGP Picks
View all

Actinic keratosis treatment market to reach $4.94B by 2030

Oct. 28, 2026
Actinic keratosis treatment market to reach $4.94B by 2030
By AI, Created 13:45 UTC, Oct 28, 2026, AGP -

The actinic keratosis treatment market is projected to grow from $3.41 billion in 2025 to $4.94 billion by 2030, according to The Business Research Company. Demand is being driven by more UV-related cases, wider use of minimally invasive therapies and growing adoption of topical and photodynamic treatments.

Why it matters: - Actinic keratosis treatment is becoming more important as skin-health awareness rises and more patients look for faster, less invasive care. - The market’s projected 7.7% annual growth points to expanding demand for therapies that can reduce the risk of progression to more serious skin conditions. - Growth in the market also reflects broader adoption of dermatology services, homecare options and minimally invasive procedures.

What happened: - The Business Research Company said the global actinic keratosis treatment market is expected to grow from $3.41 billion in 2025 to $3.67 billion in 2026. - The market is forecast to reach $4.94 billion by 2030, maintaining a 7.7% compound annual growth rate. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region over the forecast period.

The details: - Actinic keratosis treatment targets lesions that typically appear on sun-exposed areas such as the face, scalp, backs of the hands and chest. - The lesions are caused by prolonged ultraviolet radiation exposure. - The main treatment goal is to lower the risk of progression to more serious skin conditions. - Historical growth came from higher actinic keratosis incidence linked to UV exposure, limited early treatment choices, greater dermatology awareness campaigns, wider use of cryotherapy and laser therapies, and more availability of prescription drugs. - Future growth is expected to be supported by innovative topical and photodynamic treatments, more investment in dermatology clinics, broader use of combination therapies, expansion of homecare and self-administration options, and advances in minimally invasive procedures. - Expected market trends include greater adoption of topical medications, stronger preference for photodynamic therapy, increased use of fluorouracil, imiquimod and diclofenac, growth of specialized dermatology and laser centers, and more public awareness of sun protection and homecare regimens. - The company offered a free sample report and the full market report.

Between the lines: - The market story is less about a single breakthrough and more about steady demand across multiple treatment types. - Rising interest in minimally invasive care is helping support uptake among older patients, especially in developed markets where quicker recovery and less pain matter. - The shift toward homecare and self-administration suggests more treatment may move outside traditional clinic settings. - A cited example from April 2025 showed the British Association of Aesthetic Plastic Surgeons reported a 5% increase in cosmetic surgical procedures from 2023 to 2024, reaching 27,462 surgeries.

What's next: - The market is expected to keep expanding through 2030 as topical therapies, photodynamic treatment and combination approaches gain share. - Growth in Asia-Pacific will be a key watchpoint as the region scales dermatology access and treatment adoption. - More specialized clinics and minimally invasive procedures are likely to shape how patients receive care. - The Business Research Company says its 2026 market reports include market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards, market hotspots infographics and updated trend analysis.

The bottom line: - Actinic keratosis treatment is moving into a steady growth phase, with prevention-minded care, less invasive therapies and broader treatment access driving the market forward.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

UK Healthcare Gazette

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

UK Healthcare Gazette

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.